Skip to main content
SpringerLink
Log in

„Multi-targeting drugs“ und „multi-drug targeting“ beim metastasierten Nierenzellkarzinom

Konzept einer Co-Inhibition des „epidermal growth factor receptors“

  • AUO
  • Published:
Der Urologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Atkins D, Rohde D, Störkel S (2006) Differential expression of EGFR and TGF-alpha in VHL-mutated renal cell carcinomas of the clear cell type: implications for targeted therapeutic approaches. Targeted Oncol (in press)

  2. Beeram M, Rowinsky EK, Weiss GR et al. (2004) Durable disease stabilization and antitumor activity with OSI-774 in ranl cell carcinoma: a phase II, pharmacokinetic (PK) and biological correlative study with FDG-PET imaging. Proc ASCO 2004: 3050

    Google Scholar 

  3. Dawson NA, Guo C, Zak R, Dorsey B, Smoot J, Wong J, Hussain A (2004) A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 10: 7812–7819

    Article  PubMed  Google Scholar 

  4. Escudier B, Szczylik C, Eisen T et al. (2005) Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43–9006) in patients with advanced RCC. Presented at ECCO 13, Paris, 03.11.2005

  5. Hudes G (2005) New perspectives in the treatment of RCC. Pfizer Satellite symposium, ECCO 13, 31.10.2005, Paris

  6. Kobayashi S, Boggon TJ, Dayaram T et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8): 786–792

    Article  PubMed  Google Scholar 

  7. Lynch TJ, Bell DW, Sordella R et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21): 2129–2139

    PubMed  Google Scholar 

  8. Motzer RJ, Amato R, Todd M et al. (2003) Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21(1): 99–101

    Article  PubMed  Google Scholar 

  9. Motzer RJ, Rini MI, Michaelson MD et al. (2005) Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Proc ASCO 2005: 4508

    Google Scholar 

  10. Rowinsky EK, Schwartz GH, Golob JA et al. (2005) Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22(15): 3003–3015

    Article  Google Scholar 

Download references

Interessenkonflikt:

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Urologische Klinik, Klinikum, Grafenstraße 9, 64278, Darmstadt

    D. Rohde

Authors
  1. D. Rohde
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Rohde.

Additional information

D. Rohde: Vorstandsmitglied der AUO.

Association for Urogenital Oncology (AUO): “Multi-targeting drug” and “multi-drug targeting” in metastatic renal cell carcinoma. Co-inhibition of EGF-R

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rohde, D. „Multi-targeting drugs“ und „multi-drug targeting“ beim metastasierten Nierenzellkarzinom. Urologe 45, 356–358 (2006). https://doi.org/10.1007/s00120-006-1011-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-006-1011-0

Search

Navigation